301246 宏源药业
2024/06 - 中期2023/122022/122021/122020/12

盈利能力分析
净资产收益率 ROE (%)0.8232.69322.93334.50824.362
总资产报酬率 ROA (%)0.6231.83013.78623.60714.554
投入资产回报率 ROIC (%)0.7052.14417.43629.96419.244

边际利润分析
销售毛利率 (%)13.95212.98723.32433.63538.444
营业利润率 (%)4.6505.14123.25634.75824.885
息税前利润/营业总收入 (%)4.3514.63122.63034.80825.032
净利润/营业总收入 (%)3.9874.24221.06931.29919.739

收益指标分析
经营活动净收益/利润总额(%)116.50090.91266.07865.527107.935
价值变动净收益/利润总额(%)6.16122.60635.56734.909-4.826
营业外收支净额/利润总额(%)-0.823-7.190-0.410-0.622-6.090

偿债能力分析
流动比率 (X)2.6233.5001.2611.6671.874
速动比率 (X)2.4223.2910.9941.0441.190
资产负债率 (%)25.63222.84545.45331.01132.393
带息债务/全部投入资本 (%)13.04511.75428.0927.3969.960
股东权益/带息债务 (%)652.247733.974244.4231,188.820856.758
股东权益/负债合计 (%)290.144337.728120.007222.464208.712
利息保障倍数 (X)-16.658-28.042-42.601131.15915.892

营运能力分析
应收账款周转天数 (天)49.53045.92839.14327.24827.299
存货周转天数 (天)49.57554.81083.884125.130141.735